Early detection of pancreatic cancer using exosome-based biomarkers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to validate a novel method for the noninvasive early detection of pancreatic ductal adenocarcinoma (PDAC) by analyzing exosomes that contain specific microRNAs. The researchers have previously identified a combination of 13 miRNAs that can accurately detect early-stage PDAC. In this larger international cohort study, they will test the effectiveness of this exosome-based miRNA signature in identifying PDAC at its earliest stages. The study will include patients with histologically confirmed PDAC and non-disease controls who have undergone standard diagnostic procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)
* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)

Exclusion Criteria:

* Lack of written informed consent.

Where it's running

• Translational Genomics Research Institute
  Phoenix, Arizona, United States Recruiting
• City of Hope Medical Center
  Monrovia, California, United States Recruiting
• OSF HealthCare
  Peoria, Illinois, United States Recruiting
• Ochsner Medical Center
  Jefferson, Louisiana, United States Recruiting
• Atlantic Health System
  Morristown, New Jersey, United States Recruiting
• AHN Cancer Institute at Allegheny General Hospital
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Ajay Goel, PhD — City of Hope Medical Center
• Study coordinator: Ajay Goel, PhD
• Email: AJGOEL@COH.ORG
• Phone: 6262183452

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating tumor types in pancreatic cancer patients receiving FOLFIRINOX treatment

  This study is testing how different types of pancreatic cancer respond to the chemotherapy FOLFIRINOX before surgery to see if it helps make the tumors easier to remove.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT03977233

• Microwave Ablation Feasibility for pancreatic and liver cancers guided by endoscopic ultrasound

  This study tests whether an ultrasound-guided microwave ablation device can be safely and effectively used in adults with locally advanced, unresectable, or metastatic pancreatic or liver cancers.

  Recruiting Banner Health · Gilbert, Arizona and 5 other locations · NCT07817147

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Dual-target CAR-T therapy targeting mesothelin and CLDN18.2 for advanced pancreatic cancer

  This treatment will try sequential CAR‑T cell infusions that target mesothelin and CLDN18.2 in people with unresectable or metastatic pancreatic adenocarcinoma who have received prior systemic therapy.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07066995

• Investigating microRNA for diagnosing and treating pancreatic cancer

  This study is testing whether certain tiny molecules in the blood can help doctors diagnose pancreatic cancer earlier and see how well treatments are working for patients.

  Recruiting Nuvance Health · Norwalk, Connecticut · NCT04406831

• Registry for pancreatic cysts at UCSF

  This study is setting up a registry to track patients with pancreatic cysts to see how these cysts change over time and to help doctors make better treatment decisions.

  Recruiting University of California, San Francisco · San Francisco, California · NCT04291651

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.